Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level

We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.[Image: see text]

Detalles Bibliográficos
Autores principales: Miyauchi, Masaaki, Toyoda, Masao, Zhang, Jie, Hamada, Naoko, Yamawaki, Takashi, Tanaka, Jun, Harada, Kazuki, Kashizaki, Fumihiro, Fukagawa, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232357/
https://www.ncbi.nlm.nih.gov/pubmed/31587459
http://dx.doi.org/10.1111/jdi.13143
_version_ 1783535369410576384
author Miyauchi, Masaaki
Toyoda, Masao
Zhang, Jie
Hamada, Naoko
Yamawaki, Takashi
Tanaka, Jun
Harada, Kazuki
Kashizaki, Fumihiro
Fukagawa, Masafumi
author_facet Miyauchi, Masaaki
Toyoda, Masao
Zhang, Jie
Hamada, Naoko
Yamawaki, Takashi
Tanaka, Jun
Harada, Kazuki
Kashizaki, Fumihiro
Fukagawa, Masafumi
author_sort Miyauchi, Masaaki
collection PubMed
description We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.[Image: see text]
format Online
Article
Text
id pubmed-7232357
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72323572020-05-19 Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level Miyauchi, Masaaki Toyoda, Masao Zhang, Jie Hamada, Naoko Yamawaki, Takashi Tanaka, Jun Harada, Kazuki Kashizaki, Fumihiro Fukagawa, Masafumi J Diabetes Investig Letters to the Editor We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.[Image: see text] John Wiley and Sons Inc. 2019-10-06 2020-05 /pmc/articles/PMC7232357/ /pubmed/31587459 http://dx.doi.org/10.1111/jdi.13143 Text en © 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Letters to the Editor
Miyauchi, Masaaki
Toyoda, Masao
Zhang, Jie
Hamada, Naoko
Yamawaki, Takashi
Tanaka, Jun
Harada, Kazuki
Kashizaki, Fumihiro
Fukagawa, Masafumi
Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
title Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
title_full Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
title_fullStr Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
title_full_unstemmed Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
title_short Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
title_sort nivolumab‐induced fulminant type 1 diabetes with precipitous fall in c‐peptide level
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232357/
https://www.ncbi.nlm.nih.gov/pubmed/31587459
http://dx.doi.org/10.1111/jdi.13143
work_keys_str_mv AT miyauchimasaaki nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT toyodamasao nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT zhangjie nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT hamadanaoko nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT yamawakitakashi nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT tanakajun nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT haradakazuki nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT kashizakifumihiro nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel
AT fukagawamasafumi nivolumabinducedfulminanttype1diabeteswithprecipitousfallincpeptidelevel

Ejemplares similares